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Abstract
CYP3A4 and CYP4A5 share specificity for a wide range of xenobiotics with the CYP3 
subfamily collectively involved in the biotransformation of approximately 30% of all 
drugs. CYP3A4/5 mRNA transcripts have been reported in the skin, yet knowledge of 
their protein expression and function is lacking. In this study, we observed gene and 
protein expression of CYP3A4/5 in both human skin and tissue- engineered skin equiv-
alents (TESEs), and enzyme activity was detected using the model substrate benzyl- O- 
methyl- cyanocoumarin. Mass spectrometric analysis of TESE lysates following 
testosterone application revealed a time- dependent increase in metabolite produc-
tion, confirming the functional expression of these enzymes in skin.
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1  | BACKGROUND
Cytochrome P450 (CYP450) enzymes are a superfamily of haemo-
proteins that metabolize a multitude of endogenous and xenobiotic 
molecules and are essential to maintain homoeostasis.[1,2] As the most 
highly expressed xenobiotic enzymes in the liver, they are responsi-
ble for the majority of phase I reactions, metabolizing between 70% 
and 80% of all drugs.[3,4] The CYP3 subfamily of the CYP450 enzymes, 
comprising of CYP3A4, CYP3A5, CYP3A7 and CYP3A43, are col-
lectively involved in the metabolism of over a third of these drugs.[4] 
CYP3A4, the most abundantly expressed isoform in the liver,[5] has 
a large active site that enables its interaction with a wide range of 
structurally diverse compounds and permits metabolism of such mol-
ecules and drugs as hormones (testosterone, oestrogen), anticancer 
drugs (paclitaxel, tamoxifen) and antifungal agents (ketoconazole) 
amongst others.[4,6] CYP3A5 shares 85% amino acid sequence homol-
ogy with CYP3A4 and displays similar substrate specificity.[7] Gene 
expression of CYP3A4 and CYP3A5 has been detected in skin and 
tissue- engineered skin equivalents (TESEs) by genomic analysis in 
some studies [8,9,S1,S2] but not others,[S3] and to date, protein expres-
sion has not been detected.[S4,S5] Given the use of skin as a drug deliv-
ery route, it is extremely important to determine functional expression 
of CYP3A4/5. Moreover, the increasing use of TESE as an alternative 
to animal testing for drug irritation and sensitivity assays has led to 
their proposed use in drug- induced toxicity assays. However, data on 
functional xenobiotic enzyme activity in these models are lacking and 
urgently required.
2  | QUESTIONS ADDRESSED
The relative gene and protein expression of CYP3A4 and CYP3A5 in 
human skin in comparison with liver remains unclear. It is also un-
known whether the expression is localized to the dermis or epidermis 
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and whether the enzymes are functionally active and are able to me-
tabolize clinically relevant molecules.
3  | EXPERIMENTAL DESIGN
See Appendix S1.
4  | RESULTS
Gene expression levels of CYP3A4 and CYP3A5 were in much 
greater abundance in the liver than skin with expression being sev-
eral hundred- fold greater for CYP3A4 and ninefold for CYP3A5, re-
spectively (Figure 1A,B). In human liver, gene expression of CYP3A4 
was significantly greater (P < .001) than for CYP3A5, whereas, in 
skin, gene expression of CYP3A5 was significantly greater (P < .001) 
than that of CYP3A4 (Figure 1A,B). Immunoblot analysis revealed 
that both enzymes were also expressed at markedly lower levels in 
skin compared to liver (Figure 1C,D), confirming the qPCR data. An 
immunopositive band corresponding to CYP3A5 was not detected in 
skin at exposure times that were saturating for liver samples; how-
ever, when probed in isolation, CYP3A5 was detected when the ex-
posure time was extended to increase assay sensitivity (Figure 1E). 
mRNA transcripts for CYP3A4 and CYP3A5 were detected in TESE. 
Gene expression levels for CYP3A4 were very low and several 
hundred- fold lower than for CYP3A5, and similar to native skin, 
TESE expressed significantly more mRNA transcripts for CYP3A5 
than CYP3A4 (P < .001) (Figure 1F), and significantly more CYP3A4 
(P < .05) and CYP3A5 (P < .01) was expressed in the epidermis com-
pared to the dermis (Figure 1G,H). Immunohistochemical analysis 
showed that CYP3A4 was equally distributed throughout the epider-
mis although absent in the cornified layers of both skin and TESE 
(Figure S1A,B). CYP3A4 staining was also observed in the majority 
of stromal fibroblasts and was prominent in the endothelium lining 
the blood vessels within the connective tissue of native skin (Figure 
S1A). In contrast, staining was not observed in the fibroblasts popu-
lating the collagen hydrogel in the TESE (Figure S1B), supporting the 
qPCR data that showed very low mRNA expression in the TESE der-
mis. In native skin, expression of CYP3A5 was largely restricted to 
F IGURE  1 Comparison of gene and protein expression levels 
between human liver, skin and TESE for CYP3A4 and CYP3A5. 
cDNA from human liver and skin was subjected to qPCR analysis 
for CYP3A4 (blue) and CYP3A5 (red) and gene expression relative 
to GAPDH determined for (A) liver and (B) skin. Protein expression 
in liver and skin was resolved by immunoblotting for (C) CYP3A4 
and (D) CYP3A5. (E) CYP3A5 expression in skin following prolonged 
exposure during infrared detection of immunopositive bands; β- actin 
was used as a loading control, and immunoblots are representative 
of 3 independent experiments. F, Relative gene expression of 
CYP3A4 (blue) and CYP3A5 (red) in whole EpiDerm- FT400™ TESE 
by qPCR analysis. RNA from the epidermis and dermis of EpiDerm- 
FT400™ TESE was isolated, reverse transcribed and subjected to 
qPCR analysis for (G) CYP3A4 and (H) CYP3A5. Data are relative 
expression to GAPDH. Data are mean ± SD for n = 3 independent 
experiments and 3 technical repeats per experiment. *P < .05, 
**P < .01, ***P < .001 by ANOVA
F IGURE  2 Functional activity of CYP3A in (A) liver, (B) skin and 
(C) TESE and testosterone metabolism by TESE. Protein extracts were 
generated from human liver, skin and EpiDerm- FT400™ TESE and 
subjected to kinetic enzyme analysis using increasing concentrations 
of the model substrate benzyl- O- methyl- cyanocoumarin (BOMCC). A 
Nelder- Mead algorithm was used to fit the enzyme activity data, and 
all data sets were fit with the assumption that Km (the binding affinity 
for the substrate at half the maximum velocity) was the same in each 
assay (Km = 10 μmol/L). Maximum velocity (Vmax) was calculated as 
specific metabolic activity of CYP3A in μmol/min/mg. Data are from 
three independent experiments performed in triplicate. Goodness- 
of- fit R2 values are as follows: (A) .8855, (B) .9779 and (C) .9962. 
Testosterone was added either to (D) the surface of the epidermis 
to mimic topical drug deliver or (E) added to the medium that bathes 
the dermis to mimic systemic drug delivery. The production of the 
specific testosterone metabolite 6β- OH- testosterone was measured 
by mass spectrometry in epidermal and dermal extracts as well as 
the tissue culture medium after 8 and 24 hours. Data are from 2 
independent experiments and 3 technical repeats per experiment
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the stratum basale (Figure S1C) whereas expression in TESE models 
was extremely weak throughout the entire epithelium (Figure S1D). 
The discordant in immunostaining and qPCR data is likely due to low 
antibody affinity for CYP3A5. Both native skin and TESE revealed 
no staining in the dermis, suggesting that dermal fibroblasts do not 
express CYP3A5.
Liver extracts exhibited a maximal reaction velocity (Vmax) of 
6694 μmol/min/mg whilst native human skin extracts exhibited a 
lower Vmax of 3215 μmol/min/mg. The Vmax of TESE was approxi-
mately half that of native skin (1788 μmol/min/mg). Assuming that the 
enzyme catalytic rate (Kcat) for CYP3A for this substrate is the same in 
liver, skin and TESE, we can use these Vmax estimates to calculate the 
relative tissue/extract enzyme expressions, namely skin:liver = 0.48:1; 
TESE:liver = 0.267:1; TESE:skin = 0.556:1 (Figure 2A- C).
Testosterone was applied to the stratum corneum or to the cul-
ture medium of TESE for 8 and 24 hours to mimic topical or systemic 
delivery. TESE models were separated into epidermal and dermal 
components, and extracts of these along with the conditioned me-
dium were analysed by mass spectrometry for presence of the CYP3A- 
generated metabolite, 6β- OH- testosterone. When testosterone was 
applied topically, 6β- OH- testosterone was detected in the epider-
mis,  dermis and culture medium at both 8 and 24 hours. At 8 hours, 
6β- OH- testosterone levels were similar in the epidermis, dermis and 
 medium, whereas after 24 hours, the levels of 6β- OH- testosterone 
found in the epidermis were markedly lower, in the dermis were sim-
ilar and in the medium had increased fivefold compared to levels at 
8 hours (P < .001) (Figure 2D). A markedly different pattern of me-
tabolite production was observed when testosterone was added to 
mimic systemic delivery. In these models, the presence of 6β- OH- 
testosterone was not detected in the epidermal or dermal compart-
ments at 8 or 24 hours, whereas after 8 hours, 6β- OH- testosterone 
was detected in the culture medium and these levels were significantly 
increased after 24 hours (P < .001) (Figure 2E).
5 | CONCLUSIONS
In this study, we show both gene and protein expression of predomi-
nantly CYP3A5 but also CYP3A4 in native skin and TESE. These data 
have important clinical implications for dermal drug delivery of existing 
or new compounds, in particular those with structural components that 
are likely to be metabolized by CYP3A4/5. They also show that, although 
expressed at lower levels than skin, TESEs are able to replicate the kinet-
ics of skin metabolism of topically and systemically delivered drugs.
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SUPPORTING INFORMATION
Additional Supporting Information may be found online in the sup-
porting information tab for this article.
FIGURE S1 Spatial localization of metabolizing enzyme expression in 
native skin and TESE. Formalin- fixed, paraffin- embedded sections of 
native human skin and EpiDerm- FT400™ TESE were analysed by im-
munohistochemistry to determine the spatial expression of CYP3A4 
(A & B) and CYP3A5 (C & D). IgG was used as a control (E & F). Scale 
bar = 100 μm. Images are representative of 3 independent experi-
ments from 3 different tissues
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